Depression studies

Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major depressive disord...

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

France, United Kingdom, Bulgaria, + 8 others

Sponsor

H. Lundbeck A/S

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i...

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

Countries

Bulgaria, Estonia, Germany, + 4 others

Sponsor

HMNC Holding GmbH

A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, United Kingdom, Germany, + 3 others

Sponsor

Takeda Global Research & Development Centre (Europe) Ltd.

A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepress...

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Germany, Hungary, + 2 others

Sponsor

Alkermes, Inc.

A study on the safety, tolerability, and effects of GM-2505

This study isn't currently recruiting.

Countries

Netherlands

Sponsor

Gilgamesh Pharmaceuticals

An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Czechia, Finland, + 4 others

Sponsor

Intra-Cellular Therapies, Inc.

Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder. A 6-week randomised, double-blind parallel groups study versus ...

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, United Kingdom, Austria, + 2 others

Sponsor

Institut de Recherches Internationales Servier

Exploring the Pharmacomicrobiomics of Depression

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

Countries

Netherlands

Sponsor

Radboudumc

Helsinki improved transcranial magnetic stimulation for depression

This study isn't currently recruiting.

Countries

Finland

Sponsor

Hospital District of Helsinki and Uusimaa

Controlled study of electroconvulsive therapy (ECT) with pharmacotherapy or pharmacotherapy alone in relapse prevention of depression

This study isn't currently recruiting.

Countries

Sweden

Sponsor

Orebro County Council (Orebro lans landsting) (Sweden)

STEPS study: to find out if and how to carry out a large clinical trial on stepped care treatment for depression

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

University of Exeter (UK)

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

This study has finished and is no longer accepting participants.

Countries

United States

Sponsor

Cybin IRL Limited